Neuroblastoma is a childhood cancer that can be inherited, but the genetic aetiology is largely unknown. Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired. We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees. Resequencing of regional candidate genes identified three separate germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight separate families. Resequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples. Nine of the ten mutations map to critical regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers. Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK messenger RNA resulted in profound inhibition of growth in all cell lines harbouring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK. Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy.
Neuroblastoma is a cancer of early childhood that arises from the developing autonomic nervous system. It is the most common malignancy diagnosed in the first year of life and shows a wide range of clinical phenotypes, with a few patients having tumours that regress spontaneously, whereas most patients have aggressive metastatic disease 1 . These latter neuroblastoma cases have survival probabilities of less then 40% despite intensive chemoradiotherapy, and the disease continues to account for 15% of childhood cancer mortality 1, 2 . Tumours from patients with an aggressive phenotype often show amplification of the MYCN oncogene 3 , and/or deletions of chromosome arms 1p and 11q (ref. 4) . However, because MYCN is so aberrantly dysregulated, and no putative tumour suppressor gene at 1p and 11q has been shown to harbour inactivating mutations in more than a small percentage of cases, no tractable molecular target approaches at present exist for this disease.
Like most human cancers, a small subset of neuroblastoma cases is inherited in an autosomal dominant manner [5] [6] [7] . A family history of the disease is found in about 1-2% of newly diagnosed cases, with a standardized incidence ratio of 9.7 for siblings of index cases 8 . Neuroblastoma pedigrees show notable heterogeneity in the type of tumours that arise, with both benign and malignant forms occurring in the same family 9 . Familial neuroblastoma patients differ from those with sporadic disease in that they are diagnosed at an earlier age and/or with several primary tumours, clinical characteristics that are hallmarks of cancer predisposition syndromes. Because of the lethality of the condition before reproductive age, previous genetic linkage scans have been underpowered and results have been difficult to replicate [10] [11] [12] . Notably, neuroblastoma can occur with a spectrum of disorders related to abnormal development of neural-crestderived tissues, including central congenital hypoventilation syndrome and Hirschsprung's disease. Missense or nonsense mutations in PHOX2B, a homeobox gene that is a master regulator of normal autonomic nervous system development, were recently shown to predispose to this rare field defect of the sympathoadrenal lineage tissues [13] [14] [15] . However, PHOX2B mutations explain only a small subset of hereditary neuroblastoma, are almost exclusive to cases with associated disorders of neural-crest-derived tissues, and are not somatically acquired in tumours 16, 17 , leaving the genetic aetiology for most familial neuroblastoma cases unknown.
Identification of germline ALK mutations
To identify the location of a hereditary neuroblastoma predisposition gene, we performed a genome-wide scan for linkage at ,6,000 single nucleotide polymorphisms (SNPs) in 20 neuroblastoma families. Because of the rarity of the condition, the genome-wide scan included pedigrees with varying degrees of confidence of actual heritability. Eight families had three or more affected individuals of close relation (high confidence), six families consisted of only two individuals of first-degree relation (moderate confidence), and six other families also only had two affected individuals, but of a more distant relationship (low confidence). We discovered a significant linkage signal at chromosome 2p, with a maximum non-parametric likelihood ratio (lod) score of 4.23 at rs1344063 in 18 of the families (two were excluded owing to insufficient DNA). This refined a region previously reported for one of the pedigrees studied here 10 . By mapping informative recombination events, we defined a predisposition locus at chromosome bands 2p23-p24 delimited by SNPs rs1862110 and rs2008535 with 104 genes including the known neuroblastoma oncogene, MYCN 3, 18 , and the ALK oncogene located 13.2 megabases (Mb) centromeric. Despite previous work showing that forced overexpression of MYCN to the murine neural crest causes neuroblastoma 18 , resequencing of the MYCN coding region and 18 kilobases (kb) of surrounding genomic DNA in probands from each linked family showed no disease-causal sequence variations.
We next focused on the ALK gene because our group and others had previously identified it as a potential oncogene in neuroblastoma through somatically acquired amplification of the genomic locus 19, 20 . In addition, oncogenic fusion proteins leading to constitutive activation of the ALK kinase domain occur in many human cancers including anaplastic large cell lymphoma 21 , inflammatory myofibroblastic tumours 22 , squamous cell carcinomas 23 and non-small-cell lung cancers 24, 25 . Resequencing of the 29 ALK coding exons identified three separate single base substitutions in the ALK tyrosine kinase domain in eight of the probands screened ( Fig. 1 and Table 1 ). These DNA sequence alterations were not present in either single nucleotide polymorphism (dbSNP; http://www.ncbi.nlm.nih.gov/projects/ SNP/) or somatic mutation (COSMIC; http://www.sanger.ac.uk/ genetics/CGP/cosmic/) databases, and were not detected in direct sequencing of the ALK tyrosine kinase domain in 218 normal control alleles. Each substitution was subsequently shown to segregate with the disease in each family (Fig. 1) . The sequence variation in family FNB12 (R1275Q) seems to have been acquired de novo in the affected father, and non-paternity was excluded by analysis of inheritance of genotypes in this pedigree. There are several asymptomatic obligate carriers identified (FNB2, FNB13, FNB32, FNB52 and FNB56), suggesting that the incomplete penetrance of this disease may be due to lack of the acquisition of a second genetic event such as amplification of the mutant allele, or alternatively, spontaneous regression following malignant transformation in at least a subset of cases. Notable is the very large multiplex family (FNB52), with discordance in twins and several unaffected carriers, which segregates a unique germline mutation (G1128A).
ALK sequence variations occurred only in the families with high or moderate degrees of confidence for harbouring a predisposing allele. Six of the eight families with three or more affected individuals had ALK missense alterations. The two families that did not have ALK sequence alterations identified were each shown to harbour mutations in the sympathoadrenal lineage-specific PHOX2B neurodevelopmental gene 14, 16 . Two of the six families consisting of only two affected individuals, but of first-degree relation, had ALK sequence variations. Each of these families carried the R1275Q alteration, and in FNB12 we showed that the mutation arose de novo in the affected father, whereas in FNB56 the alteration was inherited from an unaffected father (Fig. 1) . None of the six families with two distant relations affected with neuroblastoma showed ALK alterations, suggesting that the occurrence of a further case of this relatively rare disease in an extended family member was probably a chance occurrence. Because there are several families who share identical mutations, we looked to see if these families shared a common haplotype around the ALK gene and showed that the affected individuals with the same mutations did not share haplotypes, arguing against a founder effect.
Because ALK functions as an oncogene in other human cancers, we predicted that the sequence variations discovered in the neuroblastoma pedigrees would result in constitutive activation. We therefore used a support vector machine-based statistical classifier to map the putative mutations and determine the probability that they would act as drivers of an oncogenic process 26, 27 . Each of the germline alterations occurred at regions of the ALK kinase domain that have been shown to be principal targets for cancer driver mutations in other (Table 1 and Fig. 2 ). The R1275Q mutation was present in the germline DNA of affected individuals from five pedigrees (Fig. 1) , and falls within the kinase activation loop in a region strongly associated with activating mutations in many different protein kinases, such as BRAF 28 . This amino acid substitution results in an electropositive residue being replaced by a more electronegative one, possibly mimicking activating phosphorylation events. The R1192P mutation occurred at the beginning of the b4 strand of the kinase domain, and although it is predicted to be a driver mutation with high confidence (Table 1) , the mechanism for activation is not yet clear 27 . The G1128A was seen only in the large pedigree with affected individuals in a single generation. The variation falls at the third glycine of the glycine loop, and identical mutations of this glycine residue to alanine in BRAF have been shown to increase kinase activity 29 .
Identification of somatic ALK mutations
Having shown that heritable mutations in the ALK tyrosine kinase domain are associated with a highly penetrant predisposition to develop neuroblastoma, we next sought to determine whether ALK activation might also be somatically acquired. We examined a representative set of 491 sporadically occurring primary neuroblastoma samples acquired from children at the time of diagnosis on a 550K SNP-based microarray to assess for genome-wide copy number alterations. A total of 112 cases (22.8%) showed unbalanced gain of a large genomic region at 2p including the ALK locus (partial trisomy), and an additional 16 cases (3.3%) showed high-level focal amplification of ALK (Fig. 3) . Each of the high-level amplifications co-occurred with MYCN amplification and/or other regions at 2p, except one case with an ALK amplicon only. The presence of aberrant ALK copy number status (gain or amplification) was highly associated with an aggressive clinical phenotype such as metastasis at diagnosis (P , 0.0001) and death from disease (P 5 0.0003).
Because of the association of ALK gain and amplification with high-risk disease features, we next examined a subset of 167 tumour samples from high-risk patients, and 27 human neuroblastomaderived cell lines (all from high-risk patients), for sequence alterations in the ALK tyrosine kinase domain. A total of 14 of the 167 tumour (8.4%) and 10 of the 27 cell line (35.7%) samples showed single base substitutions consistent with activating mutations (Fig. 2) . Eight separate single base substitutions were identified, with the R1275Q mutation being the only mutation also seen in the germline DNA of the families studied. Again, none of the sequence variations discovered here was in SNP databases or was identified in our resequencing of the ALK tyrosine kinase domain in 109 control subjects (218 alleles). Mutations were equally distributed between cases with and without MYCN amplification. Only one case had a co-occurrence of an ALK mutation (F1174L) and genomic amplification of the ALK locus, and in this case the mutated allele was amplified (data not shown). Germline DNA was available for 9 out of 14 patients with ALK mutations, and in one of these cases the sequence alteration (I1250T) was also present in the germ line, suggesting a hereditary predisposition that may or may not be de novo in this case.
Using the same statistical classifier used for the germline mutations, we showed that all but one of the sequence variations discovered in the tumour tissues were predicted to be activating mutations (Table 1) , and the one that showed a low probability (D1091N) was outside the core kinase domain. Most of the somatically acquired mutations fell into either the catalytic loop or the C-helix kinase domains, both frequent sites for oncogenic activating mutations indicating protein structure of ALK, with mutations discovered in constitutional DNAs of familial cases (germ line) and primary tumours from sporadic cases (somatic) indicated. All but one sequence alteration mapped to the tyrosine kinase (TK) domain (D1091N was just amino-terminal and is not indicated here). Of the three germline mutations discovered, only the R1275Q was found in the tumour DNA samples. Conversely, the I1250T mutation discovered in the tumour set was also present in the matched germline DNA of that patient, whereas all of the other mutations studied here were somatically acquired. aa, amino acids; SP, signal peptide; TM, transmembrane. b, Homology model of wild-type ALK with each main subdomain indicated 26, 27 . c, ALK mutations mapped onto homology model (different orientation from b to show all mutations), with colours indicating the subdomain (identified in b) in which the mutation resides (for example, the R1275Q mutation falls within the activation segment, indicated in green). (Fig. 2) . Catalytic loop mutants, especially I1250T, may promote oncogenesis by altering substrate binding or, most probably, by altering packing of the HRD and DFG motifs towards an activated conformation 30 . The mutations observed in the ALK C-helix domain occurred at positions within the kinase domain previously found to be mutated in other tumours. I1171N falls at an equivalent weakly oncogenic position in MET (M1149T) 31 , and the M1166R, F1174I and F1174L mutants fall at equivalent positions mutated in ERBB2 (D769, V777) and EGFR (D761, V769) [32] [33] [34] .
Functional consequences of ALK mutations
We have previously shown that ALK is differentially expressed in human primary neuroblastomas with higher expression generally seen in the most aggressive subset of tumours 35 . Using quantitative polymerase chain reaction with reverse transcription (RT-PCR) we confirmed that ALK is highly expressed in all but one of the 20 human neuroblastoma-derived cell lines. ALK expression was higher in neuroblastoma cells compared to developing fetal brain, and the cell lines harbouring ALK mutations (n 5 6) expressed the mRNA at a significantly higher copy number than the ALK wild-type cell lines (n 5 14, Fig. 4a ). Analysis of protein lysates from a panel of neuroblastoma cell lines showed constitutive phosphorylation of the tyrosine residue at codon 1604 in each of the cell lines harbouring mutations, with weak phosphostaining in two wild-type cell lines (Fig. 4b) .
To determine whether ALK activation by mutation and/or amplification is functionally relevant in models of high-risk neuroblastoma-and thus might offer a tractable therapeutic target-we examined the consequences of disrupting ALK signalling by mRNA knockdown. We transiently transfected short interfering RNAs (siRNAs) directed against ALK (Dharmacon) into ten neuroblastoma cell lines and screened for inhibition of substrate adherent growth. We demonstrated knockdown of the mRNA and protein in all cell lines studied, but showed differential effects on cellular proliferation (Fig. 5a-l) . Each of the cells harbouring ALK mutation or amplification showed profound inhibition of proliferation to ALK knockdown. In addition, two of the six ALK wild-type cell lines showed significant inhibition of growth with ALK knockdown and each of these had shown weak evidence for phosphorylation at tyrosine 1604 (Fig. 4b) , indicating that an alternative mechanism may have resulted in ALK kinase activation in these two cell lines.
Discussion
Knudson and Strong predicted that neuroblastoma, like the analogous embryonal cancer retinoblastoma, would follow a two-hit model explaining hereditary and sporadic cases 5 . This model has proved to be correct for most childhood and adult hereditary cancers, and the susceptibility genes are typically tumour suppressors in which the two hits are the sequential inactivation of both alleles. The discovery of heritable mutations in oncogenes as the aetiology of multiple endocrine neoplasia type 2 cancers (RET), papillary renal carcinoma (MET) and gastrointestinal stromal tumours (KIT) challenged this model, but it is now clear that somatically acquired duplication or amplification of the mutant allele provides the second hit 36 . We have shown that heritable mutations in ALK are the cause of most hereditary neuroblastoma cases, providing, to our knowledge, the first example of a paediatric cancer arising because of mutations in an oncogene. Together with our recent report that common variations at chromosome band 6p22 predispose to the development of sporadic neuroblastoma 37 , the genetic aetiology of this disease is now being defined. The discovery of highly penetrant, heritable ALK mutations as the cause of hereditary neuroblastoma is of immediate relevance to patients with a family history; screening with noninvasive techniques such as ultrasonography and measurement of urinary catecholamine metabolites should probably be implemented for unaffected children carrying an ALK mutation. In addition, continuing efforts to characterize the full spectrum of mutations in the entire ALK coding sequence, as well as determining the frequency of mutations across all neuroblastoma disease subsets, will be required to formulate genetic screening recommendations for newly diagnosed neuroblastoma patients with or without a family history.
ALK is an orphan tyrosine kinase transmembrane receptor with homology to neurotrophin receptors and the MET oncogene. Its expression is restricted to the developing nervous system with a postulated role in participating in the regulation of neuronal differentiation 38 . It is now clear that many human cancers activate ALK signalling by creating unique oncogenic fusions of ALK with a variety of partners through chromosomal translocation events 39 . Previous work had shown that a substantial percentage of human-derived neuroblastoma cell lines express ALK transcripts and ALK protein 40 , but no definitive role for this oncogene had been proven 19, [41] [42] [43] . ALK was recently identified as a molecular target in neuroblastoma by a screen of human cancer cell lines with pharmacological antagonists of the ALK kinase domain 44 . Our current report provides evidence for oncogenic activation of ALK by mutation of the kinase domain, and these data provide the genetic basis for the observation of sensitization to ALK kinase inhibition. In addition, our discoveries in neuroblastoma may lead to future resequencing efforts in other malignancies, especially those in which oncogenic fusion proteins have recently been discovered. The data presented here clearly establish ALK as a critical neuroblastoma oncogene and should increase efforts to identify the ligand for this receptor and to determine whether ALK-mediated signalling can be activated by mechanisms other than direct mutation and/or amplification of ALK alleles. Furthermore, receptor tyrosine kinases provide tractable targets for pharmacological inhibition, and this work should provide the impetus for developing therapeutic strategies aimed at inhibiting ALK-mediated signalling.
METHODS SUMMARY
Twenty probands with neuroblastoma and a family history of the disease were identified. Eight pedigrees had three or more affected individuals; six pedigrees contained only two affected individuals, but of first degree relation; and six pedigrees consisted of only two affected individuals, but of second, third or $fourth degree relationship. A total of 176 individuals (49 affected with neuroblastoma) were genotyped genome-wide, and two families were excluded owing to insufficient DNA for genotyping. We simulated marker data under a model of genetic homogeneity and autosomal dominant inheritance, and analysed the data using an affected-only approach comparable to the model-free approach used in the actual linkage analysis. Genotype data were checked for Mendelian inconsistencies using PedStats 45 , and analysed for linkage using Merlin 46 and Lamp 47 . Regional candidates were re-sequenced using Sanger methodology. Predictions on the probability that DNA sequence alterations encode a mutant protein were performed using a support vector machine-based statistical classifier 26, 27 . Four-hundred-and-ninety-one primary tumour samples and 27 cell lines were used for whole genome SNP-array analyses (550K) to determine copy number alterations 37 . mRNA knockdown of ALK and control targets was achieved with siRNAs against each target. The effects of siRNA knockdown on substrate adherent growth was quantified using the RT-CES microelectronic cell sensor system (ACEA) 48, 49 . Whole cell lysates were collected from the cell lines and from cells treated with either ALK siRNA or non-targeting control after transfection. Proteins were separated by SDS-PAGE gels and immunoblotted using anti-ALK and anti-phospho-ALK antibodies.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
